Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
34 hedge funds and large institutions have $4.09M invested in Acorda Therapeutics in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 3 closing their positions.
114% more capital invested
Capital invested by funds: $1.91M → $4.09M (+$2.18M)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
3% more funds holding
Funds holding: 33 → 34 (+1)
62% less call options, than puts
Call options by funds: $25K | Put options by funds: $66K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TI
Telemetry Investments
New York
|
+$77.2K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$73.9K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$19.8K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$12.2K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$10.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCA
Canyon Capital Advisors
Dallas,
Texas
|
-$357K |
| 2 |
Prudential Financial
Newark,
New Jersey
|
-$16.8K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$14.6K |
| 4 |
VF
Virtu Financial
New York
|
-$6K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.57K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Russell Investments Group
London,
United Kingdom
| $4.6K | – | – | – |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $4K | -$5.57K | -478 | -63% |
|
28
Morgan Stanley
New York
| $3.82K | -$1K | -86 | -26% |
|
29
Citigroup
New York
| $272 | -$629 | -54 | -75% |
|
30
First Manhattan
New York
| $38 | – | – | – |
|
|
IAS
31
IMA Advisory Services
Denver,
Colorado
| $13 | – | – | – |
|
|
JFA
32
JNBA Financial Advisors
Bloomington,
Minnesota
| $1 | – | – | – |
|
|
CCA
33
Canyon Capital Advisors
Dallas,
Texas
| – | -$357K | -59,699 | Closed |
|
|
VF
34
Virtu Financial
New York
| – | -$6K | -1,071 | Closed |
|
35
BNP Paribas Financial Markets
Paris,
France
| – | -$181 | -30 | Closed |
|
36
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$12 | -1 | -6% |
|
37
Rockefeller Capital Management
New York
| – | +$93 | +8 | New |
|
ACOR Hedge Fund Activity: Q4 2022 in Review
34 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q4 2022, worth a combined $4.09M — up 114% from $1.91M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ACOR positions and 3 closed out — a net gain of 1 holder — while 9 added to existing stakes and 8 trimmed.
The largest buyer was Telemetry Investments, opening a new position worth an estimated $77.2K. The largest seller was Canyon Capital Advisors, exiting entirely with an estimated $357K sold.
- 34 institutional investors held Acorda Therapeutics (ACOR) as of Q4 2022, up from 33 in Q3 2022.
- Funds reported $4.09M of Acorda Therapeutics stock for Q4 2022, up 114% quarter-over-quarter.
- 4 funds opened new Acorda Therapeutics positions in Q4 2022 and 3 closed out, a net change of +1 holder.
- The largest Acorda Therapeutics buyer in Q4 2022 was Telemetry Investments, an estimated $77.2K added.
- The largest Acorda Therapeutics seller in Q4 2022 was Canyon Capital Advisors, an estimated $357K sold.
Based on aggregated 13F filings for Q4 2022.